Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

• US 10,682,345 B2
• Filed: 05/08/2019
• Issued: 06/16/2020
• Est. Priority Date: 06/18/2014
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Albrecht, Balazs, Aven, Michael, Lamar, Janine
• Primary Examiner(s): Otton, Alicia L
• Application Number:
  US16/406,918
• Publication Number:
  US 20190262329A1
• Time in Patent Office: 405 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 35/06 Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61M 15/009 using medicine packages with incorporated spraying means, e.g. aerosol cans pocket atomiser of the injector type A61M11/08
• CPC Class Codes: A61M 2250/00 Specially adapted for animals
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.

Claims

1. A composition in the form of a liquid formulation and comprising:

a solvent comprising a mixture of water and ethanol, wherein ethanol is present in the solvent in an amount of 90-95% V/V;

a glucocorticoid comprising ciclesonide or a pharmaceutically acceptable salt thereof; and

a long-acting muscarinic antagonist (LAMA) or a pharmaceutically acceptable salt of the cation thereof having the following formula;

2. The composition of claim 1, further comprising a long-acting beta-2 adrenergic agonist (LABA) or a pharmaceutically acceptable salt thereof and selected from the group consisting of salmeterol, formoterol, bambutterol, indacaterol, vilanterol, abediterol and olodaterol hydrochloride.

3. The composition of claim 1, further comprising a pharmaceutically acceptable excipient.

4. The composition according to claim 1, wherein the LAMA is a compound of the formula:

5. The composition of claim 1, wherein the concentration of LAMA ranges between 0.3 to 6.0% m/V of the total composition.

6. The composition of claim 1, wherein the concentration of LAMA ranges between 0.4 to 5% m/V of the total composition.

7. The composition of claim 1, wherein the glucocorticoid further comprises budesonide or a pharmaceutically acceptable salt thereof.

8. The composition of claim 1, wherein the liquid formation comprises a solution for inhalation.